[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinal-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinal-tumor":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,59,92,121,147,172,196,217,244],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100528530","phase-2-study-of-olutasidenib-and-temozolomide-in-hgg-100528530",false,"NCT06161974","Study of Olutasidenib and Temozolomide in HGG","Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations","Criteria TarGeT-D study strata definitions\n\n* Stratum A: Patients with localized, intracranial, non-pontine, and non-thalamic IDH 1 mutant Astrocytoma, CNS WHO Grade 3.\n* Stratum B: Patients with localized, intracranial, non-pontine, and non-thalamic IDH 1 mutant Astrocytoma, CNS WHO Grade 4.\n* Stratum C: Patients with IDH-1 mutant DIPG, primary thalamic and spinal cord IDH-1 mutant HGG.\n\nInclusion Criteria:\n\n1. Inclusion criteria already met to enroll on TarGeT-SCR (central molecular and histopathologic screening) based on:\n\n   1.1) Age: patients must be ≥12 years and ≤39 years of age at the time of enrollment on TarGeT-SCR 1.2) Diagnosis:\n   * Patients with a newly-diagnosed IDH1-mutant HGG including DIPG are eligible. All patients must have tumor tissue from diagnostic biopsy or resection, without exceptions. The diagnosis of HGG, including DIPG, must have been confirmed through TarGeT-SCR.\n   * For the diagnosis of DIPG, patients must have a tumor with pontine epicenter and diffuse involvement of at least 2\u002F3 of the pons, and histopathology consistent with diffuse WHO Grade 2-4 glioma.\n   * All other HGG must be WHO Grade 3 or 4.\n\n   1.3) Disease status: There are no disease status requirements for enrollment\n   * Measurable disease is not required. Patients without measurable disease are eligible.\n   * Primary spinal tumor: Patients with a primary spinal HGG are eligible.\n   * Patient must not have metastatic disease.\n2. Inclusion criteria for assignment to TarGeT-D, for all strata:\n\n2.1 Presence of at Least One Relevant Actionable Somatic Mutation in IDH1 Gene, Detailed Here:\n\n* R132H, R132C, R132S, R132G or R132L.\n* Patients whose tumors harbor other alterations in addition to IDH1 mutation will potentially be eligible following consensus recommendation by the international multidisciplinary molecular screening committee.\n* Patients with IDH2 mutations are not eligible.\n* Patients with oligodendroglioma, IDH-mutant and 1p\u002F19q-codeleted are not eligible.\n\n2.2 Weight: Patients must weigh ≥35 Kg (77 lbs) at the time of enrollment on TarGeT-D.\n\n2.3 Performance Level: Karnofsky ≥ 50% for patients \\> 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.\n\n2.4 Prior Therapy 2.4.1 Surgery, radiation, and\u002For dexamethasone are permissible. Temozolomide administered concurrently with radiotherapy is permissible. Prior administration of bevacizumab is allowed, given at least 42-day washout period is completed prior to beginning treatment on TarGeT-D. No other prior anticancer therapy for HGG will be allowed.\n\n2.4.2 Radiation therapy requirements: RT, delivered via photon or proton beam, must have been administered at a standard dose including 54 Gy in 30 fractions for DIPG, 55-59.4 Gy in 30-33 fractions for other HGG or 45-54 Gy for primary spinal cord HGG. Any variances in the radiotherapy dose within 10% of the standard doses outlined above will be discussed with the Study Chair to confirm eligibility prior to study enrollment.\n\n2.4.3 Timing between diagnosis and start of RT: Patients must have started RT \\\u003C 42 calendar days of initial diagnosis defined as the date of diagnostic biopsy or resection; if a patient underwent two upfront surgeries (e.g., biopsy then resection or debulking), this is the date of the second surgery.\n\n* Patients in pre-maintenance phase must enroll and start treatment no later than 21 calendar days post-completion of RT.\n* Patients not in pre-maintenance phase must enroll and start treatment no later than 35 calendar days post-completion of RT.\n\n2.5 Organ Function Requirements 2.5.1 Adequate Bone Marrow Function Defined as:\n\n* Peripheral absolute neutrophil count (ANC) ≥ 1000\u002Fmm3.\n* Platelet count ≥ 100,000\u002Fmm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).\n* Hemoglobin \\> 8 g\u002FdL (may be transfused). 2.5.2 Adequate Renal Function Defined as\n* Creatinine clearance or radioisotope GFR ≥ 70ml\u002Fmin\u002F1.73 m2 OR\n* Maximum serum creatinine based on age\u002Fgender as follows: 10 to \\\u003C 13 yrs=1.2 mg\u002FdL for males and females. 13 to \\\u003C 16 yrs=1.5 mg\u002FdL for males and 1.4 mg\u002FdL for females.\n\n2.5.3 Adequate Liver Function Defined as:\n\n* Total bilirubin must be ≤ 1.5 × institutional ULN.\n* AST(SGOT)\u002FALT(SGPT) \\\u003C 3 × institutional ULN.\n* Alkaline Phosphatase \\\u003C 3 × institutional ULN. 2.5.4 Adequate Neurologic Function Defined as:\n\n  * Patients with seizure disorder may be enrolled if well-controlled on anticonvulsants that are not a strong inducer or inhibitor of CYP3A4\u002F5.\n  * Patients must be able to swallow oral medications to be eligible for study enrollment.\n\n2.6. Informed consent: All patients and\u002For their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.\n\nExclusion Criteria:\n\n1. Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entered on this study due to unknown potential risks of fetal and teratogenic adverse events as seen in animal studies. Pregnancy tests must be obtained in girls who are post-menarchal. Patients of childbearing or child fathering potential must agree to use one highly effective method of contraception while being treated on this study and for 3 months after completing therapy. A woman is considered of childbearing potential if she is fertile, following menarche and until becoming post-menopausal unless permanently sterile. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy. Male participants should refrain from sperm donation throughout the duration of treatment and for 3 months after completion of therapy.\n\n   A highly effective contraception method is defined as one that results in a low failure rate (\\\u003C1% per year) when used consistently and correctly. The following are considered highly effective contraception methods:\n   * Combined estrogen and progesterone containing hormonal contraception associated with inhibition of ovulation.\n   * Progesterone-only hormonal contraception associated with inhibition of ovulation.\n   * Intra Uterine Device (IUD).\n   * Intra uterine hormone releasing system.\n   * Bilateral tubal occlusion.\n   * Vasectomized partner.\n   * Sexual abstinence (avoiding heterosexual intercourse).\n   * The following contraceptive measures are NOT considered effective:\n\n     * Progesterone-only hormonal contraception (birth control pill) that that does NOT stop ovulation.\n     * Male or female condom with or without spermicide.\n     * Cap, diaphragm, or sponge with spermicide.\n2. Using the following types of concomitant medications:\n\n   * Corticosteroids: Patients receiving corticosteroids are eligible. The use of corticosteroids must be reported.\n   * Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible.\n   * Anti-cancer Agents: Concurrent anti-cancer agents are not allowed with the exception of temozolomide given concurrently with RT and as protocol-instructed post RT maintenance therapy after enrollment on TarGeT-D.\n   * Anticonvulsants: Patients who are receiving enzyme inducing anticonvulsants that are strong inducers of CYP3A4\u002F5 are not eligible.\n   * Strong CYP3A4\u002F5 inducers: Patients who are receiving strong inducers of CYP3A4\u002F5 are not eligible. Strong inducers of CYP3A4\u002F5 should be avoided from 14 days prior to or 5 half-lives (whichever is longer) enrollment to the end of the study.\n   * Patients who are receiving medications known to prolong QTc interval are not eligible\n   * Selective serotonin reuptake inhibitors (SSRIs) such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft) should be used with caution but are not contraindicated.\n3. Other Criteria\n\n   * Infection: Patients who have an uncontrolled infection are not eligible.\n   * Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study are not eligible.\n   * Patients with known clinically significant active malabsorption syndrome or other condition that could affect absorption are not eligible.\n   * Patients with malignancy related to HIV or solid organ transplant: known history of HIV, HBV surface antigen positivity or positive HCV antibody are not eligible. Viral testing is not required unless clinically indicated in patients without a known history.\n   * Patients with prior or ongoing clinically significant illness, medical or psychiatric condition, that, in the investigator's opinion, could affect the safety of the participant, or could impair the assessment of study results are not eligible.\n   * Patients with any prior solid organ transplant are not eligible.\n   * Patients with secondary\u002Fradiation-related HGG are not eligible.\n   * Patients with metastatic\u002Fdisseminated HGG who have received CSI are not eligible.","ALL","12 Years","39 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation.\n\nThe main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"High Grade Glioma","Astrocytoma","Astrocytoma, Grade III","Astrocytoma, Grade IV","Diffuse Intrinsic Pontine Glioma","WHO Grade III Glioma","WHO Grade IV Glioma","Metastatic Brain Tumor","Diffuse Midline Glioma, H3 K27M-Mutant","Thalamus Tumor","Spinal Tumor","IDH1 Mutation","IDH1 R132","IDH1 R132C","IDH1 R132H","IDH1 R132S","IDH1 R132G","IDH1 R132L","Oligodendroglioma","RECRUITING","2026-06-10",{"date":49,"type":50},"2026-06-12","ACTUAL",{"date":52,"type":50},"2025-02-01",{"date":54,"type":21},"2035-06",{"name":56,"class":57},"Rigel Pharmaceuticals","INDUSTRY",20,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":16,"minAge":66,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":69,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100633530","the-effect-of-radiotherapy-after-separation-surgery-for-spinal-metastases-100633530","NCT07527884","The Effect of Radiotherapy After Separation Surgery for Spinal Metastases","Postoperative Radiotherapy Versus No Radiotherapy Following Separation Surgery for Spinal Metastases: A Mixed Cohort Study","Inclusion Criteria:\n\n1. Age over 18 years old, gender not limited;\n2. The patient has undergone separation surgery within 3 weeks;\n3. The pathological result of the separation surgery site of the patient indicates that the lesion is a metastatic tumor, and the primary lesion is located outside the spine;\n4. The expected survival period is ≥ 6 months;\n5. The patient has signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with poor general condition and those who are intolerant to radiotherapy, chemotherapy, and targeted therapy;\n2. Patients whose treatment segments have not received any other surgical treatment or radiotherapy;\n3. Patients who participated in other clinical trials of drugs or medical devices within 3 months before enrollment;\n4. Other situations judged by the investigator as making the subject unsuitable for enrollment.","18 Years",{"count":68,"type":21},130,[70],"NA","The aim of this clinical study is to explore the impact of whether radiotherapy is administered after spinal metastasis surgery on the prognosis and survival of patients, to describe the clinical outcomes, and to optimize future clinical decisions.",[73,37,74,75],"Spinal Metastases","Radiotherapy","Separation Surgery",[77,78,79,80],"spinal metastases","spinal tumor","radiotherapy","separation surgery","NOT_YET_RECRUITING","2026-04-09",{"date":84,"type":50},"2026-04-14",{"date":86,"type":21},"2026-05-01",{"date":88,"type":21},"2028-06-30",{"name":90,"class":91},"Shanghai Changzheng Hospital","OTHER",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":66,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":109,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":120},"100462071","post-market-clinical-follow-up-study-on-the-safety-and-performance-of-ennovate-cervical-100462071","NCT05296889","Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Cervical","Multicenter Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Cervical - a Prospective Study on Total Indications","CERISE","Inclusion Criteria:\n\n* Patient is minimum 18 years old\n* Informed Consent in the documentation of clinical and radiological results\n* Patient has indication according to Instructions for Use (IFU)\n* Patient is not pregnant\n\nExclusion Criteria:\n\n* Patient's clear unability or unwillingness to participate in follow-up examinations",{"count":101,"type":21},200,"OBSERVATIONAL","Multicenter Post market clinical follow-up Study on the Safety and Performance of Ennovate® Cervical - Prospective, pure data collection of all Ennovate Cervical patients in Total Indications",[105,106,107,37,108],"Spine Fracture","Degenerative Disc Disease","Spinal Instability","Degenerative Myelopathy",[110],"Cervical Spine","2026-03-26",{"date":113,"type":50},"2026-03-31",{"date":115,"type":50},"2021-07-21",{"date":117,"type":21},"2026-07",{"name":119,"class":57},"Aesculap AG",4,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":66,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100452385","clariance-erys-registry-100452385","NCT05170815","Clariance ErYs Registry","Clariance Registry of ERISMA® and Idys® Devices","ErYs","Inclusion Criteria:\n\n* Considered as adult in the respective geography (18 years old or older for France and 21 years old or older for United-States).\n* Indicated for treatment with one or more commercially available sponsor spine device included into the study.\n* For France only, affiliated with or beneficiary of a social security scheme.\n\nExclusion Criteria:\n\n* Subjects who are not able to comply with the study procedures based on the judgment of the investigator (e.g., inability to comprehend study related questions, inability to keep scheduled assessment times).\n* Subjects who are considered as vulnerable: minor, pregnant woman or people under legal protection (guardianship or curatorship).\n* Contraindicated for spine surgery utilizing a commercially available sponsor spine device.",{"count":130,"type":21},760,"International, prospective, single arm, multicenter and observational Post-Market Clinical Follow-up (PMCF).\n\nThe overall objective of this study is to collect preoperative, intraoperative and postoperative (at 9 weeks, 6 months, 1 year and 2 years) data on the clinical complications and functional outcomes of the study devices to demonstrate safety and performance in a real-world setting.\n\nThe primary objective is to demonstrate that the use of the study devices is safe.\n\nThe secondary objective is to demonstrate that the use of the study devices decreases the pain, and improves the quality of life and the daily activities of the subjects.",[133,134,135,37,136],"Spine Degeneration","Spine Spondylosis Thoracic","Spinal Deformity","Spinal Fracture","2026-03-16",{"date":139,"type":50},"2026-03-17",{"date":141,"type":50},"2022-01-17",{"date":143,"type":21},"2028-12",{"name":145,"class":57},"Clariance",1,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":146},"100469700","a-prospective-study-of-the-safety-and-efficacy-of-3d-printed-non-rigid-biomimetic-implant-in-cervical-and-thoracolumbar-spine-100469700","NCT05396222","A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar Spine","A Prospective Study of the Safety and Efficacy of 3D-printed Custom-made Non-rigid Biomimetic Implant for Anterior Column Reconstruction in Cervical and Thoracolumbar Spine","Inclusion Criteria:\n\n1. Age 20 - 79 years;\n2. Patient meet the indication for 1- to 3- level corpectomy, for primary bone tumor at spine, or metastatic tumor at spine.\n3. Deficit confirmed by CT, MRI, and X-ray;\n4. Pathology level located from C3 to L5.\n5. Physically and mentally able and willing to comply with the protocol;\n6. Signed informed consent;\n7. NTU Spine Multidisciplinary Board confirmed tumor excision surgery is indicated.\n8. Life expectancy longer than 6 months (Tokuhashi Scoring System)\n\nExclusion Criteria:\n\n1. Patient does not meet the indication of corpectomy, which is under the surveillance.\n2. More than three vertebrae required corpectomy;\n3. Corpectomy levels above C3 and below L5\n4. T-score less than -2.5\n5. Known allergy to device materials - such as titanium\n6. Any diseases or conditions that would preclude accurate clinical evaluation;\n7. Daily, high-dose oral and\u002For inhaled steroid or a history of chronic use of high dose steroids;\n8. BMI \\> 35\n9. Life expectancy less than 6 months - (Tokuhashi Scoring System)\n10. The subject has received radiation therapy or chemotherapy at the trial site within one year;\n11. Anterior spine surgery has been received at or near the spine surgery site;\n12. The subject has systemic infection,or focal vertebral infection or trauma;\n13. The subject has endocrine disorders or metabolic disorders known to affect bone formation, such as: Paget's disease, renal osteodystrophy, hypothyroidism;\n14. The subject has neuromuscular diseases, those at risk of instability, implant fixation failure or postoperative care complications, including: spina bifida, cerebral palsy, and multiple sclerosis;\n15. Osteopenia, osteomyelitis;\n16. Pregnant women.","20 Years","79 Years",{"count":157,"type":21},18,[70],"Vertebral body resection is a wide accepted procedure in tumor resection, deformity correction, and anterior decompression in spondylosis, ossification of posterior longitudinal ligaments, and spondylodiscitis surgery. However, reconstruction of segmental defect is still challenging to spine surgeon, especially in 3-column resection, such as total en bloc spondylectomy in tumor patients. Various graft or prosthesis for reconstruction has been reported, such as structural allograft, Harms mesh cages, expandable cages, and carbon fiber stackable cages. There are no high evidence level study examining the superiority of those different methods.\n\nRecently, 3D printed vertebral body replacement has been reported in different disease entities as well, such as tumor, Kümmell's disease in osteoporosis, and spondylosis. 3D printed implant comes with superiority in production of complex geometries and regularity of the fine surface detailed that promote bone ingrowth. Although, 3D-printed titanium vertebra could achieved bone integration in human, a systemic review showed that the subsidence noted in 31.4% of spine surgery with 3D printed implants. In spine surgery, the fixation construct is sufficiently stiff, interbody motion can be reduced, and loading sharing promotes bone fusion. On the other hand, if the reconstruction is too stiff, stress shielding at fusion site occurs. The concept of dynamic fusion, as opposed to rigid fusion, has been demonstrated by an anterior cervical interbody fusion study in porcine model, demonstrating good bone formation, less postfusion stiffness, and a trend to less subsidence.\n\nThus, we developed a 3D printed, custom-made, biomimetic prosthesis, with non-rigid structure, which has been tested in biomechanical study and porcine model, showing good bone formation and less stiffness as well. Therefore, we proposed a prospective clinical study to investigate safety, subsidence, and fusion of this prosthesis.",[37],[37,162],"Reconstruction","2025-12-16",{"date":165,"type":50},"2025-12-17",{"date":167,"type":21},"2027-01-01",{"date":169,"type":21},"2028-01-01",{"name":171,"class":91},"National Taiwan University Hospital",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":66,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":5},"100563217","separation-surgery-followed-by-stereotactic-ablative-body-radiotherapy-sabr-versus-sabr-alone-for-spinal-metastases-100563217","NCT06613295","Separation Surgery Followed by Stereotactic Ablative Body Radiotherapy (SABR) Versus SABR Alone for Spinal Metastases","Separation Surgery Followed by Stereotactic Ablative Body Radiotherapy Versus Stereotactic Ablative Body Radiotherapy Alone for Spinal Metastases Invading the Spinal Canal: a Randomised, Non-inferiority Trial","SABR-MESCC","Inclusion Criteria:\n\n* Diagnosis of a solid malignant tumour (preferentially histologically proven;alternatively obtained by spinal surgical procedure)\n* Age 18 years or older\n* Histological, radiological or scintigraphical evidence of spinal metastasis (no limitation in the number of sites of metastases)\n* Spinal instability neoplastic score (SINS) \\\u003C13 (i.e. no need for stabilisation of the spine) (see Appendix 6)\n* Spinal metastasis with MESCC: ESCC grade 1c, 2 and 3 (see Appendix 7)\n* Ambulatory: being able to walk 10m without aid or with aid (cane, rollator, one persons help).\n* Life expectancy estimated to be at least 3 months.\n* World Health Organization (WHO) Performance Status of 0-2 (some help) (see Appendix 3)\n* Patient has given written informed consent.\n\nExclusion Criteria:\n\n* Contra indication for MRI scan (e.g. pacemaker)\n* Previous RT or surgery at the level of the affected vertebrae\n* Non-solid primary tumours (e.g. lymphoma, multiple myeloma, germ cell tumours)\n* Non ambulatory at presentation\n* More than 3 affected vertebrae in one target site\n* More than 2 treatment sites\n* SINS ≥ 13 (unstable spine)",{"count":181,"type":21},128,[70],"This is a non-inferiority, randomised controlled trial to investigate the effect of stereotactic ablative body radiotherapy (SABR) compared to separation surgery followed by SABR in ambulatory patients with malignant epidural spinal cord compression (MESCC).\n\nThe primary objective of the project is investigating the effect of SABR compared to separation surgery followed by SABR in ambulatory patients with MESCC on retaining ambulatory function. The primary endpoint of the study is ambulatory function 3 months post treatment defined as: being able to walk 10m without aid; being able to walk 10m with aid (cane, rollator, one persons help, …); not being able to walk. Secondary outcomes are local control, progression free survival, early and late adverse effects, quality of life, effect on pain and need for reintervention.\n\nThe aim is to randomise 128 patients 1:1 to either \"separation surgery\" followed by SABR (5x 8.0 Gy postoperative) (control arm) vs. SABR alone (5x 8.0 Gy) (study arm).\n\nPatients will be evaluated at 3 and 6 months after treatment with MRI scan, quality of life questionnaires, anamnestic and clinical evaluation at clinical follow ups for assessment of ambulatory function, acute and late toxicity and need for reintervention. Moreover, at 6 weeks, 12 months and 24 months after treatment a teleconsult for assessment of ambulatory function, and need for reintervention will be performed.",[185,186,37],"Solid Tumor","Spinal Neoplasms","2024-09-23",{"date":189,"type":50},"2024-09-25",{"date":191,"type":50},"2022-03-07",{"date":193,"type":21},"2027-03-01",{"name":195,"class":91},"Cancer Research Antwerp",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":66,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":146},"100561197","delineation-of-target-volume-of-stereotactic-radiotherapy-for-spinal-tumors-100561197","NCT06587022","Delineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors","ST-SBRT","Inclusion Criteria:\n\n* Patients with spinal metastases or primary tumors receiving stereotactic radiotherapy;\n* Patients with sufficent pre-treatment imaging data\n* Patients who can cooperate with imaging review and follow-up after radiotherapy.\n\nExclusion Criteria:\n\n* Patients with an expected survival of less than 3 months;\n* Patients with second-course radiotherapy;\n* Patients with physical conditions that cannot tolerate stereotactic radiotherapy;\n* Patients with extensive spinal metastasis and no local therapeutic value","90 Years",{"count":205,"type":21},500,"The purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors.",[37],"2024-09-04",{"date":210,"type":50},"2024-09-19",{"date":212,"type":50},"2017-01-01",{"date":214,"type":21},"2027-12-30",{"name":216,"class":91},"Peking University Third Hospital",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":224,"sex":16,"minAge":66,"maxAge":225,"enrollmentInfo":226,"targetDuration":228,"studyType":102,"phases":4,"briefSummary":229,"conditions":230,"keywords":233,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":146},"100525337","en-bloc-resection-versus-separation-surgery-combined-with-radiotherapy-for-the-treatment-of-spinal-oligometastatic-tumor-100525337","NCT06120426","En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.","En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor-A Multi-center, Prospective, Randomized, Controlled Study.","Inclusion Criteria:\n\n* 1\\) Be able to sign written informed consent.\n* 2\\) Age range from 18 to 75 years old, regardless of gender.\n* 3\\) Within conservative treatment, the patient still has uncontrollable pain, metastatic cancer lesions that still progress, spinal instability\u002Fpotential instability, or symptoms of spinal cord\u002Fnerve compression.\n* 4\\) After the patient underwent Positron Emission Tomography-Computed Tomography (PET-CT) examination, it was indicated that there were no more than 3 metastatic organs and no more than 5 metastatic lesions in the whole body of cancer. Among them, there was at least 1 spinal metastasis and at most 5 spinal metastases.\n* 5\\) Imaging examinations (enhanced MRI, enhanced CT, X-ray) indicate the presence of spinal metastasis.\n* 6\\) The expected survival period is ≥ 6 months.\n* 7)No other surgical contraindications\n\nExclusion Criteria:\n\n* 1\\) Primary tumors of the spine or multiple tumors of the body, with\\>3 metastatic organs and\\>5 metastatic sites.\n* 2\\) Previously underwent spinal surgery, or received radiotherapy for the responsible segment of this treatment.\n* 3\\) Severe heart, lung, liver, kidney or other diseases affecting the surgery.\n* 4\\) Having cognitive impairment, sensory aphasia, and inability to understand basic instructions.\n* 5\\) Participated in clinical trials of other drugs or medical devices within 3 months prior to enrollment.\n* 6\\) Infectious diseases.\n* 7\\) Refuse to follow up or participate.\n* 8\\) The researchers determine that the patients are not suitable for enrollment this clinical trail.",true,"75 Years",{"count":227,"type":21},182,"2 Years","The purpose of this clinical trial is to explore the impact of En bloc surgery and separation surgery combined with radiation therapy on the prognosis and survival of patients with spinal oligometastatic cancer, describe the clinical results, and optimize future treatment goals",[73,37,74,231,232],"Malignant Bone Tumor","Surgery",[234,235],"Total enbloc spondylectomy","Oligometastases","2023-11-09",{"date":238,"type":50},"2023-11-13",{"date":240,"type":50},"2023-07-01",{"date":242,"type":21},"2027-07-01",{"name":90,"class":91},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":66,"maxAge":250,"enrollmentInfo":251,"targetDuration":253,"studyType":102,"phases":4,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":146},"100467662","stereotactic-radiosurgery-prognosis-assessment-for-spinal-tumors-based-on-radiomics-100467662","NCT05369689","Stereotactic Radiosurgery Prognosis Assessment for Spinal Tumors Based on Radiomics","Inclusion Criteria:\n\nA diagnosis of spinal tumors for which SBRT is appropriate Karnofsky Performance Status \\>60 Life expectancy of at least 3 months No contraindication to undergoing MR imaging Age \\>18 Complete the CT MRI or PET-CT examination before and after treatment Accept stereotactic radiosurgery\n\nExclusion Criteria:\n\nSubjects unable to undergo MRI (includes non-MRI compatible material or devices and severe claustrophobia) Subjects with prior procedural intervention to the involved vertebral body that would result in artifact (kyphoplasty, screw and\u002For rod placement); minimally invasive surgery without instrumentation of the involved vertebral body and instrumentation immediately above or below the index lesion is allowed.\n\nSubjects with spinal cord compression; minimally invasive \"separation\" surgery to first resect the epidural component is allowed Pregnant or breast-feeding women Allergy to standard IV contrast agents used in MRI","80 Years",{"count":252,"type":21},300,"5 Years","This study aims to assess multimodal Radiomics-based prediction model for prognostic prediction in spinal tumors.",[256,37,257,258],"Stereotactic Radiosurgery","Radiomics","Prognosis","2022-05-07",{"date":261,"type":50},"2022-05-11",{"date":263,"type":21},"2022-06-01",{"date":265,"type":21},"2027-06-01",{"name":267,"class":91},"Zhuang Hongqing"]